ReviewThe oncologist2009
NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.
Review in The oncologist, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003594 (A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.Journal of the National Cancer Institute · 2016Article
- Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice.Trials · 2015Review
- Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.Drug safety · 2013Article
- Data for cancer comparative effectiveness research: past, present, and future potential.Cancer · 2012Review
- Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.British journal of cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
N9741 is a clinical trial in patients with metastatic colorectal cancer that was originally written in 1997 and completed patient accrual in 2004. One thousand seven hundred thirty-one patients were enrolled in the study. During the conduct of the trial, N9741 was repeatedly modified to adapt to toxicity findings, to add evaluation of oxaliplatin to what was originally a trial examining various schedules of irinotecan-based therapy, and to ask evolving questions. The trial led to a new U.S. Food and Drug Administration indication for 5-fluorouracil, leucovorin, and oxaliplatin as indicated for the treatment of previously untreated patients with metastatic colorectal cancer and helped to change the standard of care for the disease in the U.S. and worldwide. The data from the trial have been used to study multiple regimens, pharmacogenetics, and quality of life issues, to correlate plasma protein levels with outcomes, to inform trial methodology, and to perform economic analyses. To date nearly 30 papers and an even larger number of abstracts have been based upon data arising from the study. The history of the trial and the major findings are summarized in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.